tiprankstipranks
Trending News
More News >
Kiora Pharmaceuticals (KPRX)
NASDAQ:KPRX
US Market
Advertisement

Kiora Pharmaceuticals (KPRX) Drug Pipeline

Compare
477 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Kio-104
Macular Edema
Phase II
Recruiting
Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema
Feb 04, 2025
100 Μg Kio-301, 50 Μg Kio-301
Retinitis Pigmentosa
Phase II
Recruiting
A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
Oct 03, 2024
Kio-301
Retinitis Pigmentosa, Choroideremia
Phase I/II
Recruiting
A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)
Mar 08, 2022

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does Kiora Pharmaceuticals (KPRX) have in its pipeline
      KPRX is currently developing the following drugs: Kio-104, 100 Μg Kio-301, 50 Μg Kio-301, Kio-301. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis